These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25371395)

  • 41. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study.
    Jamnitski A; Levels JH; van den Oever IA; Nurmohamed MT
    J Rheumatol; 2013 Jun; 40(6):825-30. PubMed ID: 23637327
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.
    Kobie JJ; Zheng B; Bryk P; Barnes M; Ritchlin CT; Tabechian DA; Anandarajah AP; Looney RJ; Thiele RG; Anolik JH; Coca A; Wei C; Rosenberg AF; Feng C; Treanor JJ; Lee FE; Sanz I
    Arthritis Res Ther; 2011; 13(6):R209. PubMed ID: 22177419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
    Tang B; Rahman M; Waters HC; Callegari P
    Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 47. Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population.
    Zervou MI; Myrthianou E; Flouri I; Plant D; Chlouverakis G; Castro-Giner F; Rapsomaniki P; Barton A; Boumpas DT; Sidiropoulos P; Goulielmos GN
    PLoS One; 2013; 8(9):e74375. PubMed ID: 24040234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
    Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Anti-TNF therapy in rheumatoid arthritis].
    Yakeuchi T; Amano K
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Feb; 27(1):7-15. PubMed ID: 15045810
    [No Abstract]   [Full Text] [Related]  

  • 50. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy.
    Chen DY; Chen YM; Chen HH; Hsieh CW; Lin CC; Lan JL
    Arthritis Res Ther; 2011 Jul; 13(4):R126. PubMed ID: 21801431
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
    Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R;
    Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
    Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G;
    J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TNFalpha inhibitors may improve asthma symptoms: a case series of 12 patients with rheumatoid arthritis and asthma.
    Stoll ML; Solomon DH; Batra KL; Simard JF; Karlson EW; Dellaripa PF; Weinblatt ME; Glass R; Shadick NA
    J Clin Rheumatol; 2009 Jun; 15(4):198-200. PubMed ID: 19455057
    [No Abstract]   [Full Text] [Related]  

  • 57. IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor α inhibitors in rheumatoid arthritis.
    Sakthiswary R; Shaharir SS; Mohd Said MS; Asrul AW; Shahril NS
    Int J Rheum Dis; 2014 Nov; 17(8):872-7. PubMed ID: 25292482
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance.
    Stagakis I; Bertsias G; Karvounaris S; Kavousanaki M; Virla D; Raptopoulou A; Kardassis D; Boumpas DT; Sidiropoulos PI
    Arthritis Res Ther; 2012 Jun; 14(3):R141. PubMed ID: 22691241
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.